Last update 23 Jan 2025

Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.

Private Company|
2019|
Zhejiang Sheng, China

Overview

Tags

Immune System Diseases
Respiratory Diseases
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases1
Top 5 Drug TypeCount
Chemical drugs1
Top 5 TargetCount
GSNOR(alcohol dehydrogenase 5 (class III), chi polypeptide)1

Related

2
Drugs associated with Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
JKN-23051
Target
GSNOR
Mechanism
GSNOR inhibitors
Active Org.
Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
Originator Org.
Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
Active Indication
Asthma
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
N-91115
Target-
Mechanism-
Active Org.-
Originator Org.
Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
Active Indication-
Inactive Indication
Asthma
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
CTR20243291
/ Not yet recruitingPhase 2
一项评价JKN23051在控制不佳的中、重度哮喘患者中的有效性和安全性的多中心、随机、双盲、安慰剂对照Ⅱa期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase IIa clinical study to evaluate the efficacy and safety of JKN23051 in patients with poorly controlled moderate to severe asthma
CTR20240270
/ CompletedPhase 1
评价 JKN23051 在健康受试者中的单次、多次给药的安全性、耐受性、药代动力学的单中心、随机、双盲、安慰剂对照 I 期临床试验
[Translation] A single-center, randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of JKN23051 in healthy subjects
CTR20201787
/ CompletedPhase 1
评价N91115在健康受试者中的药代动力学特征以及安全性、耐受性的随机双盲、安慰剂对照I期临床研究
[Translation] A randomized, double-blind, placebo-controlled phase I clinical study to evaluate the pharmacokinetic characteristics, safety and tolerability of N91115 in healthy subjects
100 Clinical Results associated with Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
Login to view more data
100 Deals associated with Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Langyu Pharmaceutical Technology (Hangzhou) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
JKN-23051
 ( GSNOR )		Asthma
More
Phase 2
N-91115
Asthma
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free